Makindus’ MI-100 granted EMA orphan drug designation for treatment of Stargardt’s Disease
Makindus, Inc. a specialty pharmaceutical development company focused on ophthalmology announced today that the European Medicines Agency has granted orphan drug designation for their lead candidate, MI-100, for the treatment of Stargardt's Disease.